Shares of Dynavax took off this morning after the developer announced new data demonstrating the effectiveness of its experimental therapy for ragweed allergies. Ragweed allergy sufferers were given the therapy--AIC--for six weeks and typically experienced a reduction in symptoms for 12 months. Dynavax shares jumped 26 percent. "The demonstrated therapeutic properties and safety pave the way for a therapeutic intervention that is qualitatively superior to standard immunotherapy," said Dr. Peter Creticos, lead researcher in the trial and a physician at Johns Hopkins.
- read the report from TheStreet